Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement

Molecular Immunology

Volumn 44, Issue 8, 2007, Pages 1819-1826

  Nielsen, Erik Waage ^a,b   Waage, Christian ^a   Fure, Hilde ^a   Brekke, Ole L ^a,b   Sfyroera, Georgia ^d   Lambris, John D ^d   Mollnes, Tom E ^a,b,c  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

C1 inhibitor; Complement system

Indexed keywords

BERINERT P; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT INHIBITOR; COMPSTATIN; IMMUNOGLOBULIN G; LECTIN; SNAKE VENOM; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNOSE BINDING LECTIN;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; LIQUID; PRIORITY JOURNAL; SERUM; SOLID; CHEMISTRY; COMPARATIVE STUDY; COMPLEMENT LECTIN PATHWAY; DRUG EFFECT; METABOLISM; PHYSIOLOGY; REPERFUSION INJURY; SEPSIS;

COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C4; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; REPERFUSION INJURY; SEPSIS;

EID: 34848884555     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.10.003     Document Type: Article

References (45)

1. Agostoni A., Bergamaschini L., Martignoni G., Cicardi M., and Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann. Allergy 44 (1980) 299-301
2. Ambrus G., Gal P., Kojima M., Szilagyi K., Balczer J., Antal J., Graf L., Laich A., Moffatt B.E., Schwaeble W., Sim R.B., and Zavodszky P. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J. Immunol. 170 (2003) 1374-1382
3. Bergamaschini L., and Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol. Immunol. 40 (2003) 155-158
4. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52 (2000) 91-112
5. Davis III A.E., Cai S., and Liu D. The biological role of the C1 inhibitor in regulation of vascular permeability and modulation of inflammation. Adv. Immunol. 82 (2004) 331-363
6. De Serres J., Groner A., and Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert((R)) P) in hereditary angioedema: a review. Transfus. Apheresis. Sci. 29 (2003) 247-254
7. De Simoni M.G., Rossi E., Storini C., Pizzimenti S., Echart C., and Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164 (2004) 1857-1863
8. De Vries B., Walter S.J., Peutz-Kootstra C.J., Wolfs T.G.A.M., Van Heurn L.W.E., and Buurman W.A. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am. J. Pathol. 165 (2004) 1677-1688
9. Doekes G., Van-Es L.A., and Daha M.R. C1 inactivator: its effciency as a regulator of classical complement pathway activation by soluble IgG aggregates. Immunology 49 (1983) 215-222
10. Donaldson V.H., and Evans R.R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am. J Med. 35 (1963) 37-44
11. Donaldson V.H., and Rosen F.S. Action of complement in hereditary angioneurotic edema: role of C1-esterase. J. Clin. Invest. 43 (1964) 2204-2213
12. Fiane A.E., Videm V., Lingaas P.S., Heggelund L., Nielsen E.W., Geiran O.R., Fung M., and Mollnes T.E. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation 108 7 (2003) 849-856
13. Gronski P., Bodenbender L., Kanzy E.J., and Seiler F.R. C4-binding protein prevents spontaneous cleavage of C3 in sera of patients with hereditary angioedema. Complementary 5 (1988) 1-12
14. Gulati S., Sastry K., Jensenius J.C., Rice P.A., and Ram S. Regulation of the Mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1-Inhibitor and {alpha}2-macroglobulin. J. Immunol. 168 (2002) 4078-4086
15. Harboe M., Garred P., Borgen M.S., Stahl G.L., Roos A., and Mollnes T.E. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin. Exp. Immunol. 144 (2006) 512-520
16. Harboe M., Ulvund G., Vien L., Fung M., and Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138 (2004) 439-446
17. Jiang H., Wagner E., Zhang H., and Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194 (2001) 1609-1616
18. Jordan J.E., Montalto M.C., and Stahl G.L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104 (2001) 1413-1418
19. Kawasaki N., Kawasaki T., and Yamashina I. A serum lectin (mannan-binding protein) has complement-dependent bactericidal activity. J. Biochem. (Tokyo) 106 (1989) 483-489
20. Kirschfink M., and Mollnes T.E. C1-Inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert. Opin. Pharmacother. 2 (2001) 1073-1083
21. Klein J. Complement. In: Klein J. (Ed). Immunology (1990), Blackwell Scientific Publication, London 188-226
22. Landerman N.S., Webster M.E., Becker E.L., and Ratcliffe H.E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy 33 (1962) 330-341
23. Liu D., Zhang D., Scafidi J., Wu X., Cramer C.C., and Davis III A.E. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 105 (2005) 2350-2355
24. Lynch N.J., Roscher S., Hartung T., Morath S., Matsushita M., Maennel D.N., Kuraya M., Fujita T., and Schwaeble W.J. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of gram-positive bacteria, and activates the lectin pathway of complement. J. Immunol. 172 (2004) 1198-1202
25. Matsushita M., and Fujita T. Activation of the classical complement pathway by Mannose-binding protein in association with a novel C1s-like serine protease. J. Exp. Med. 176 (1992) 1497-1502
26. Matsushita M., Thiel S., Jensenius J.C., Terai I., and Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 165 (2000) 2637-2642
27. Mollnes T.E. Analysis of in vivo complement activation. In: Herzenberg L.A., Weir D.M., and Blackwell C. (Eds). Weir's handbook of experimental immunology (1997), Blackwell Science, Cambridge, MA, USA
28. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., and Lambris J.D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
29. Nielsen E.W., Johansen H.T., Gaudesen Ø., Osterud B., Olsen J.O., Hogasen K., Hack C.E., and Mollnes T.E. C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients. Scand. J. Immunol. 42 (1995) 679-685
30. Nielsen E.W., Johansen H.T., Hogasen K., Wuillemin W.A., Hack C.E., and Mollnes T.E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand. J. Immunol. 44 (1996) 185-192
31. Pensky J., Levy L.R., and Lepow I.H. Partial purification of a serum inhibitor of C'1-esterase. J. Biol. Chem. 236 (1961) 1674-1679
32. Petersen S.V., Thiel S., Jensen L., Steffensen R., and Jensenius J.C. An assay for the mannan-binding lectin pathway of complement activation. J. Immunol. Methods 257 (2001) 107-116
33. Petersen S.V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., and Jensenius J.C. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 37 (2000) 803-811
34. Presanis J.S., Hajela K., Ambrus G., Gal P., and Sim R.B. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol. Immunol. 40 (2004) 921-929
35. Sahu A., Kay B.K., and Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157 (1996) 884-891
36. Schoenmakers S.H., Reitsma P.H., and Spek C.A. Blood coagulation factors as inflammatory mediators. Blood Cells Mol. Dis. 34 (2005) 30-37
37. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., and Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 296 (2005) 187-198
38. Souza D.G., Pinho V., Pesquero J.L., Lomez E.S., Poole S., Juliano L., Correa Jr. A., De A.C., and Teixeira M.M. Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br. J. Pharmacol. 139 (2003) 129
39. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., and Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162 (2003) 449-455
40. Terai I., Kobayashi K., Matsushita M., Fujita T., and Matsuno K. Alpha 2-Macroglobulin binds to and inhibits mannose-binding protein-associated serine protease. Int. Immunol. 7 (1995) 1579-1584
41. Thiel S., VorupJensen T., Stover C.M., Schwaeble W., Laursen S.B., Poulsen K., Willis A.C., Eggleton P., Hansen S., Holmskov U., Reid K.B., and Jensenius J.C. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386 (1997) 506-510
42. Weiser M.R., Williams J.P., Moore Jr. F.D., Kobzik L., Ma M., Hechtman H.B., and Carroll M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183 (1996) 2343-2348
43. Williams J.P., Pechet T.T., Weiser M.R., Reid R., Kobzik L., Moore F.D.J., Carroll M.C., and Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 86 (1999) 938-942
44. Zhang M., Austen Jr. W.G., Chiu I., Alicot E.M., Hung R., Ma M., Verna N., Xu M., Hechtman H.B., Moore Jr. F.D., and Carroll M.C. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. PNAS 101 (2004) 3886-3891
45. Ziccardi R.J. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol. 128 (1982) 2505-2508